Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565378 · ClinicalTrials.gov registry record · Phase 2
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
A Phase 2 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT05565378: Active Phase 2 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
NCT05565378 is a Phase 2 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 351 participants, below the 433-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05565378, a Phase 2 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Dostarlimab
- DRUG Belrestotug
- DRUG Nelistotug
Study Locations (20)
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Cipoletti Rio Negro
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
- GSK Investigational Site - Florida
- GSK Investigational Site - Mar del Plata
- GSK Investigational Site - San Juan
- GSK Investigational Site - Santa Fe
- GSK Investigational Site - Wilrijk
- GSK Investigational Site - Barretos
- GSK Investigational Site - Porto Alegre
- GSK Investigational Site - São Paulo
- GSK Investigational Site - Vitória
- GSK Investigational Site - Oulu
- GSK Investigational Site - Tampere
- GSK Investigational Site - Turku
Florida
- GSK Investigational Site - Plantation
New Mexico
- GSK Investigational Site - Albuquerque
Tennessee
- GSK Investigational Site - Chattanooga
West Virginia
- GSK Investigational Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 2 |
What the registry record for NCT05565378 still lists
NCT05565378 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 433-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05565378 names 20 study sites across 5 states, led by Other, Florida, New Mexico.
Frequently Asked Questions
What is clinical trial NCT05565378 about?
NCT05565378 is a clinical study titled "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer". This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Dru...
What is the current status of trial NCT05565378?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2022-10-14. Estimated completion is 2027-02-26.
What conditions does trial NCT05565378 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT05565378?
The interventions under investigation include: Pembrolizumab (DRUG), Dostarlimab (DRUG), Belrestotug (DRUG), Nelistotug (DRUG).
Who is sponsoring clinical trial NCT05565378?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05565378 being conducted?
This trial has 20 study locations across Florida, New Mexico, Tennessee, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05565378's enrollment target sits among peer trials
351 6th of 16 higher than 11 of 16 other Lung Cancer, Non-Small Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
ACTIVE NOT RECRUITING · Phase 2
-
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
COMPLETED · Phase 2
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
RECRUITING
-
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI